A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Trial details
- Registry ID
- NCT07271667
- Drugs studied
- Emavusertib, Zanubrutinib
TrialRedline tracks 2 clinical trials sponsored by Curis, Inc.: 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesNCT07271667 | Emavusertib, Zanubrutinib | Recruiting | 2027-11Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)NCT03328078 | Emavusertib, Ibrutinib | Recruiting | 2027-07Estimated |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.